OCT is happy to announce the successful completion of a Phase I/II Clinical Trial in oncology, on a targeted antitumor compound. Thanks to OCT Team who worked on this complex study, we were able to deliver all our activities, starting from set-up phase to the data base lock in less than 1 year. Patients with ovarian cancer and lung cancer have been enrolled by 2 sites in Russia. Our vast experience in breast cancer, colorectal cancer, pancreatic cancer, gastric cancer, prostate cancer, ovarian cancer, lung cancer and many other oncology trials made OCT a CRO of choice for oncology trials in CEE region. Since OCT have conducted more than 30 studies in oncology, on-time patients enrollment in this trial was quite predictable. Our customer in this phase I/II trial was a medium-sized biotech company who needed a flexible and reliable and cost effective partner in CEE region. Being a regional CRO, OCT can act fast enough in our local environment, which guarantees speed and cost effectiveness.
OCT is devoted to provide excellent support and expertise for the conduct of clinical trials in the CEE region for pharmaceutical and biotechnological companies. We help to bring therapies to the market by providing a full range of services in clinical management and monitoring, regulatory affairs, representation of emerging Biotech and Pharma companies, study design, analysis of bioavailability and bioequivalence studies, pharmacovigilance services and innovative developing plans of biotechnological products. By combining our experience and expertise across all areas of clinical drug development, we assist our clients to become successful drug developers.
OCT employs highly qualified physicians as full-time monitors and project managers, most of whom are board certified specialists. OCTs Clinical Operations team plays a vital role in maintaining relationships with clinical investigators capable of conducting high-quality oncology clinical research at any stage. We would be glad to conduct a phase III trial for our client to continue research of this novel targeted antitumor medication.